The use of topical medications and their alterations in patients with uveitis during the COVID-19 pandemic
| Agent | Number of eyes receiving treatment (ongoing) (n=284) | Number of eyes in whom frequency of drops was altered (increased*, initiated†) |
|---|---|---|
| Betamethasone 1% | 31 | 20*, 9† |
| Dexamethasone 0.1% | 20 | 8*, 3† |
| Prednisolone acetate 1% | 22 | 8* 3† |
| Flurbiprofen 0.3% | 19 | 4* |
| Ketorolac 0.5% | 5 | 3* |
| Nepafenac 0.1% | 20 | – |
| Atropine 1% | 42 | 12* |
| Homatropine 2% | 34 | 4* 3† |
*Indicates the patients in whom the frequency of topical medications were increased from existing therapy.
†Indicates the patients in whom new treatments were started.